Appendix A: List of Abbreviations
| Acronym/ Abbreviation | Definition |
|---|---|
| ABGs | arterial blood gasses |
| ACTG | AIDS Clinical Trials Group |
| AFB | acid-fact bacilli |
| AIN | anal intraepithelial neoplasia |
| ALT | alanine aminotransferase |
| anti-HBc | hepatitis B core antibody |
| anti-HBs | hepatitis B surface antibody |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| ASCCP | American Society for Colposcopy and Cervical Pathology |
| ASC-H | atypical squamous cells—cannot exclude high grade cervical squamous intraepithelial lesion |
| ASC-US | atypical squamous cells of uncertain significance |
| AST | serum aspartate aminotransferase |
| AUC | area under the curve |
| BA | bacillary angiomatosis |
| BAL | bronchoalveolar lavage |
| BID | twice a day |
| BIW | twice a week |
| CAP | community-acquired pneumonia |
| CAPD | continuous ambulatory peritoneal dialysis |
| CD4 | CD4 T lymphocyte cell |
| CDC | Centers for Disease Control and Prevention |
| CDI | Clostridium difficile-associated infection |
| CES-D | Center for Epidemiologic Studies Depression Scale |
| CFU | colony-forming unit |
| CIA | chemiluminescence immunoassays |
| CIN | cervical intraepithelial neoplasia |
| Cmax | maximum concentration |
| Cmin | minimum concentration |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| CPE | central nervous system penetration effectiveness |
| CrCl | creatinine clearance |
| CSF | cerebrospinal fluid |
| CT | computed tomography |
| CYP3A4 | Cytochrome P450 3A4 |
| DAAs | direct acting antiviral agents |
| DOT | directly observed therapy |
| DS | double strength |
| EDTA | ethylenediaminetetraacetic acid |
| EIAs | enzyme immunoassays |
| EM | erythema multiforme< |
| FDA | Food and Drug Administration |
| FTA-ABS | fluorescent treponemal antibody absorbed |
| g | gram |
| G6PD | Glucose-6-phosphate dehydrogenase |
| GFR | glomerular filtration rate |
| GI | gastrointestinal |
| HAV | hepatitis A virus |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HHV-8 | human herpesvirus-8 |
| HPA | hypothalamic-pituitary-adrenal |
| HPV | human papillomavirus |
| HSIL | high grade cervical squamous intraepithelial lesion |
| HSV | herpes simplex virus |
| HSV-1 | herpes simplex virus 1 |
| HSV-2 | herpes simplex virus 2 |
| ICP | intracranial pressure |
| ICU | intensive care unit |
| IFN | interferon |
| IgG | immunoglobulin G |
| IgM | immunoglobulin M |
| IGRA | interferon-gamma release assays |
| IM | intramuscular |
| IND | investigational new drug |
| IRIS | immune reconstitution inflammatory syndrome |
| IRU | immune recovery uveitis |
| IV | intravenous |
| IVIG | ntravenous immunoglobulin |
| JCV | JC virus |
| KS | Kaposi Sarcoma |
| LEEP | loop electrosurgical excision procedure |
| LP | lumbar puncture |
| LSIL | low grade squamous intraepithelial lesion |
| LTBI | latent tuberculosis infection |
| MAC | Mycobacterium avium complex |
| MAI | Mycobacterium avium intracellulare |
| MCD | multicentric Castleman’s disease |
| MDR TB | multi-drug-resistant tuberculosis |
| mg | milligram |
| mmHg | millimeters of mercury |
| MSM | men who have sex with men |
| MTB | Mycobacterium tuberculosis |
| NAA | nucleic acid amplification |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside reverse transcriptase inhibitors |
| NSAID | non-steroidal anti-inflammatory drugs |
| NVP | nevirapine |
| OI | opportunistic infection |
| PCP | Pneumocystis pneumonia |
| PCR | polymerase chain reaction |
| PEL | primary effusion lymphoma |
| PK | pharmacokinetic |
| PML | progressive multifocal leukoencephalopathy |
| PO | orally |
| PORN | Progressive Outer Retinal Necrosis |
| PPV | polysaccharide vaccine |
| PSI | pneumonia severity index |
| q(n)h | every ”n” hours |
| qAM | every morning |
| QID | four times a day |
| qPM | every evening |
| RPR | rapid plasma reagin |
| RVR | rapid virological response |
| SCr | serum creatinine |
| SJS | Stevens-Johnson syndrome |
| SLE | systemic lupus erythematosus |
| SQ | subcutaneous |
| SS | single strength |
| STD | sexually transmitted disease |
| SVR | sustained virologic response |
| TB | tuberculosis |
| TDM | therapeutic drug monitoring |
| TE | Toxoplasma encephalitis |
| TEN | toxic epidermal necrolysis |
| TID | three times daily |
| TIW | three times weekly |
| TP-PA | T. pallidum particle agglutination |
| TST | tuberculin skin test |
| ULN | upper limit of normal |
| VAIN | vaginal intra-epithelial neoplasia |
| VDRL | Venereal Disease Research Laboratory |
| VIII | vestibulocochlear |
| VIN | vulvar intraepithelial neoplasia |
| VZV | varicella zoster virus |
| WBC | white blood cell |
| WHO | World Health Organization |
| XDR TB | extensively drug-resistant tuberculosis |
| Abbreviation | Drug Name |
|---|---|
| 3TC | lamivudine |
| 5-FU | fluorouracil |
| ATV/r | ritonavir-boosted atazanavir |
| BCA | bichloroacetic acid |
| BOC | boceprevir |
| COBI | cobicistat |
| ddA-TP | dideoxyadenosine triphosphate |
| ddI | didanosine |
| DHA | dihydroartemisinin |
| EFV | efavirenz |
| EMB | ethambutol |
| EVG | elvitegravir |
| FTC | emtricitabine |
| INH | isoniazid |
| MVC | maraviroc |
| PCV13 | 13-valent pneumococcal conjugate vaccine |
| PegIFN | peginterferon alfa |
| PI | protease inhibitor |
| PPV23 | 23-valent pneumococcal polysaccharides vaccine |
| PZA | pyrazinamide |
| RAL | raltegravir |
| RBV | ribavirin |
| RFB | rifabutin |
| RIF | rifampin |
| RPT | rifapentine |
| SMX | sulfamethoxazole |
| TCA | trichloroacetic acid |
| TDF | tenofovir disoproxil fumarate |
| TMP | trimethoprim |
| TMP-SMX | trimethoprim-sulfamethoxazole |
| TVR | telaprevir |
| ZDV | zidovudine |
Download Guidelines
- Section Only PDF (260.36 KB)
- Full Guideline PDF (6.12 MB)
- Tables Only PDF (945.4 KB)